Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Novacyt ( (FR:ALNOV) ) has issued an update.
Novacyt has provided an update on its liquidity agreement with Invest Securities SA, detailing the trading of ordinary shares from 1 May to 31 May 2025. During this period, Invest Securities purchased 50,018 shares and sold 52,014 shares, with the shares held in treasury totaling 90,906 as of 31 May 2025. The total number of ordinary shares in the company is 70,626,248, which shareholders can use to determine their interest in the company. This update reflects the company’s ongoing efforts to manage its share liquidity and maintain transparency with its stakeholders.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a wide range of integrated technologies and services, primarily focusing on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation for seamless end-to-end solutions across sectors such as human health, animal health, and environmental. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, and has a global commercial presence in over 65 countries.
For detailed information about ALNOV stock, go to TipRanks’ Stock Analysis page.